Freenome, Inc. FRNM

Company Overview

Freenome, Inc. is a privately held biotechnology and healthcare technology company focused on early cancer detection through blood-based screening tests. The company operates at the intersection of molecular biology, artificial intelligence, genomics, and clinical diagnostics, with a primary emphasis on developing multiomics tests designed to detect cancer at earlier and more treatable stages. Freenome’s core business model centers on the research, development, and commercialization of noninvasive screening technologies that combine circulating biomarkers with machine learning algorithms to identify cancer-associated biological signals from blood samples.

The company was founded in 2014 and is headquartered in South San Francisco, California. Freenome initially focused on computational biology and machine learning applications in oncology diagnostics before expanding into large-scale clinical validation programs for cancer screening. Its flagship development efforts have centered on colorectal cancer detection, though the company has also explored broader multi-cancer screening applications. Freenome’s positioning in the oncology diagnostics market is tied to its integration of multiomics data analysis with proprietary AI-driven platforms intended to improve sensitivity and specificity in early cancer detection.